Nasus Pharma (NSRX) Income Statement: Revenue & Earnings

Nasus Pharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Nasus Pharma Ltd. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2024	Dec 2023	Dec 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Operating Expenses
Research & Development	0.34	0.57	1.12
Selling, General & Administrative	0.74	0.58	0.93
Operating Expenses	1.08	1.15	2.04
Operating Income	-1.08	-1.15	-2.04
Other Income/Expense
Interest Income	0.00	0.00	0.00
Interest Expense	0.03	0.05	0.02
Other Income/Expense	-0.45	0.19	-0.09
Income
Income Before Tax	-1.55	-1.01	-2.15
Income Tax Expense	0.00	0.00	0.00
Net Income	-1.53	-1.05	-1.71
Net Income - Continuous Operations	-1.55	-1.01	-2.15
Net Income - Discontinued Operations	0.02	-0.05	0.44
EBITDA	-1.52	-0.96	-2.13
EBIT	-1.52	-0.96	-2.13
Depreciation & Amortization	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	-	-
Diluted EPS	-	-	-
Basic Shares Outstanding	7.03	9.06	9.06
Diluted Shares Outstanding	7.03	9.06	9.06